Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (6802)	2/26/2001 6:24:45 AM
From: Mark Bartlett	Respond to of 14101

Wolf, That is a worse case scenario I could very easily live with .... in fact at 61.25US (heck, I'd even take Canadian) a few more doors would be opening for me. I would finally be able to write that book I have always wanted to write. I could got to the gym when it was not busy. I could give a much bigger donation to a charity I like. And high on the list; I could take you and a few others out for a beer and celebrate! MB

To: Montana Wildhack who wrote (6802)	2/26/2001 6:54:58 AM
From: Mark Bartlett	Read Replies (2) \| Respond to of 14101

Wolf, I notice you forgot to add the royalties from the sales of WF10 .... allow to me add a paragraph to your 2004 account. ~~~~~ WF10, DMX's immunomodulator drug continues to expand its potential applications. Approved in 2002 for the treatment of late-stage AIDS, it remains the only non-antiretroviral drug on the market for this purpose. Unlike the anti-retrovirals where mutations continue to be noted even with the newest drugs, this has not been with WF10. WF10 enhances the immune system (rather than attacking the virus) and thus far mutations to the AIDS virus have never been demonstrated. In addition, DMX has completed phase III trials and has submitted two NDSs for the treatment of prostate cancer and hepatitis C. The number of people in the US alone infected with hepatitis C is estimated at 4 million. Analysts expect WF10 will receive approval in these two areas due to the successful trials and the excellent safety profile of the drug. Presently WF10 is in phase III trials for MS, asthma, Crohn's disease, Systemic Lupus, post radiation treatment and lung cancer. Sales of WF10 are expected to triple in the next 24 months. Caution. This fictional account may contain forward looking statements wholly based on conjecture and brilliant forecasting of worst case scenarios. All figures in US mallards. ~~~~ Hope you do not mind that I borrowed you qualifier<G> MB